The most serious complications of untreated AFib include the following: Rapid ventricular rate (RVR) is a complication of atrial fibrillation that affects the rate at which your ventricles (two ...

“Further, we are encouraged by the interest and input from cardiology experts in our Phase 3 AFib-RVR study that we plan to commence in the first half of 2025.” As of June 30, 2024, Milestone ...

MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of ...

It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and atrial fibrillation with rapid ventricular rate (AFib-RVR).

Rodman & Renshaw launched its coverage of Canadian biopharma Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy rating and a $9 price target, citing a potential FDA nod for its lead candidate ...

“Further, we are encouraged by the interest and input from cardiology experts in our Phase 3 AFib-RVR study that we plan to commence in the first half of 2025.” As of June 30, ...

a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib ...

Milestone® (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced its licensing partner, Ji Xing ...